# Blood Cells, Hematocrit and Clotting

> What sets the fraction of your blood that is red cells, and how does a cut stop bleeding without the whole circulation clotting? This lesson separates red cell mass from plasma volume, follows erythropoietin from oxygen-sensing kidney cells to the marrow and iron back from worn-out red cells, compares two highland peoples, and builds hemostasis as a platelet plug, a thrombin burst on platelets and a set of brakes. Afterwards you can calculate red cell and iron turnover and predict which clotting assays change in hemophilia, factor XII deficiency and under drugs that block clotting.

Course: Physiology (The heart and circulation). Level: university elective. About 33 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/blood-cells-and-hemostasis/

Builds on: Body Water and Its Compartments

## What you'll learn

- Explain how red cell mass and plasma volume separately set the hematocrit of an adult human, and use them to tell a true change in red cell mass from dilution or hemoconcentration (endurance training, pregnancy, the first days at altitude).
- Trace red cell production and removal in mammals, from erythropoietin made by peritubular interstitial cells of the kidney under HIF-2 alpha to clearance by spleen and liver macrophages and iron recycling under hepcidin and ferroportin, and calculate daily red cell and iron turnover.
- Describe hemostasis in mammals as vasoconstriction, a platelet plug, the cell-based model of coagulation (initiation, amplification, a thrombin burst on platelets), the natural anticoagulant brakes and fibrinolysis.
- Predict which assays and variables change, and why, in hemophilia A and B, factor XII deficiency and high-altitude erythrocytosis, and state where aspirin, P2Y12 blockers, heparin, warfarin and direct factor Xa or thrombin inhibitors act.

**An endurance athlete can have a lower hematocrit than an untrained friend and more red cells.** Here is the second puzzle: a cut on your finger seals in a few minutes, while the same clotting proteins are flowing through every healthy vessel in your body, where nothing happens at all.

Both puzzles have the same shape: in blood, the number we measure is global and the control is local. Hematocrit is a concentration for the whole circulation, while the kidney cell that orders new red cells reads the oxygen in its own patch of tissue; a clotting time is measured on a tube of plasma, while the enzymes that seal a wound are made on the membrane of the activated platelets packed into the plug at the breach.

## Hematocrit is a ratio, not a cell count

> **The rule for the first half.** Hematocrit is a ratio, so it answers to its numerator and its denominator separately. Nothing in the body regulates the ratio. The kidney regulates the numerator, and it does so by reading the oxygen in its own interstitium — not the red cell count, and not the ratio.

Blood’s components are in [blood vessels, blood and lymph](https://stemhop.com/lessons/blood-and-vessels/). The **hematocrit** is the fraction of whole blood occupied by packed red cells after centrifugation.

> **hematocrit = red cell volume / (red cell volume + plasma volume)**

Made-up round numbers for an untrained adult, taken as a venous sample: 2.2 L of red cells and 2.8 L of plasma give 2.2 / 5.0 = 44 percent. (A hematocrit spun or counted on a venous sample runs a little above the whole-body value; see Going deeper.)

**Predict.** Training raises this person’s red cell volume by 10 percent and their plasma volume by 20 percent. Does the hematocrit go up or down, and what has happened to the number of red cells?

> **Check your prediction.** Red cell volume becomes 2.42 L and plasma volume 3.36 L, so hematocrit falls to 2.42 / 5.78 = 42 percent — with 10 percent more red cells than before. Reviews describe this pattern in trained athletes, so “sports anemia” is not anemia. The ratio fell because the denominator grew faster than the numerator.

Pregnancy also expands plasma more than red cells (pregnancy, birth and lactation). In the first days at altitude it runs the other way: diuresis shrinks plasma, and hematocrit rises before red cell mass has changed much ([control of breathing](https://stemhop.com/lessons/control-of-breathing/)). A concentration cannot give a mass: for that you need plasma volume by indicator dilution ([body fluid compartments](https://stemhop.com/lessons/body-fluid-compartments/)) or hemoglobin mass by carbon monoxide rebreathing (exercise physiology).

*Figure (AI-generated illustration).* Training adds red cells and adds even more plasma, so the hematocrit falls while the red cell mass rises: the ratio answers to its numerator and its denominator separately, and nothing in the body regulates the ratio itself. Image: Two columns of spun blood drawn as stacks of equal unit blocks. The trained column is taller in all and has more red-cell blocks at its base, yet the red-cell blocks make up a smaller share of its height than in the untrained column.

## The kidney senses oxygen, not red cells

The numerator has a controller: **erythropoietin** (EPO), a glycoprotein hormone made mostly by the adult mammalian kidney, in **fibroblast-like peritubular interstitial cells** that sit between the tubules of the cortex and outer medulla rather than in them. The evidence is in situ hybridization on anemic mouse kidneys (Lacombe and colleagues, 1988), which found Epo mRNA in peritubular cells and not in glomerular or tubular cells; those authors’ guess at the cell type was later corrected (Going deeper).

These cells read local tissue PO2. They sit in a relatively hypoxic zone, so a small fall in blood oxygen content, from anemia or low arterial PO2, lowers their oxygen enough to matter. The switch is **HIF-2 alpha**, a subunit of a hypoxia-inducible transcription factor: prolyl hydroxylases that require oxygen, iron and 2-oxoglutarate mark it for destruction in well-oxygenated cells, and when oxygen falls it accumulates and turns on the EPO gene ([ubiquitin and proteolysis](https://stemhop.com/lessons/ubiquitin-and-proteolysis/)). In rodent kidneys, hypoxia raises EPO mainly by recruiting more producing cells; human data are limited.

In lowlanders exposed to hypoxia, plasma EPO rises within the first day or two, then falls while staying somewhat above baseline. EPO acts mainly by preventing the death of late erythroid progenitors, which then divide and mature, so release of **reticulocytes** (young red cells that still hold RNA) rises over the following days. That is why the cell count lags the hormone.

Two things here are not EPO’s work. Platelets answer to **thrombopoietin**, the main regulator of megakaryocyte development. And HIF-2 alpha itself directly raises duodenal iron absorption; hypoxia lowers hepcidin too, but mostly indirectly, because the erythropoiesis EPO drives sends signals, such as erythroferrone, that suppress it.

## Red cells wear out and their iron comes back

Human red cells circulate about 120 days on average, with real variation between people. Aged cells are removed by macrophages, mainly in the **red pulp** of the spleen and in the liver; how red pulp macrophages choose which cells to take is not settled. Heme yields iron and bilirubin (absorption and the liver).

The iron leaves through **ferroportin**, the only known cellular iron exporter, and returns to the marrow on plasma transferrin; duodenal enterocytes export absorbed iron the same way. **Hepcidin**, a 25-amino-acid liver peptide secreted when iron stores rise and in inflammation, binds ferroportin: in cultured cells this drives its internalization and degradation, and structural work shows hepcidin also occludes the exporter’s central cavity.

*Figure (AI-generated illustration).* Iron runs in a loop from worn-out red cells back to the marrow, and hepcidin controls the whole loop through its one exporter, ferroportin, which sits at both exits. Image: A closed clockwise loop: marrow releases red cells into a vessel, a splenic or liver macrophage engulfs an aged red cell, and iron leaves the macrophage and a gut cell through ferroportin and travels back to the marrow on transferrin. Hepcidin blocks and removes ferroportin at both exits. An inset shows ferroportin open and then internalized.

**Predict.** A patient with a chronic inflammatory illness has iron in their macrophages, a low plasma iron concentration, and a marrow behaving as though iron were scarce. Where is the iron stuck?

> **Check your prediction.** Inflammation raises hepcidin, hepcidin removes ferroportin from the surface, and iron recovered from old red cells cannot leave the macrophage. Stores full, plasma empty: the plasma number reports one gate, not the total — the global-and-local theme again. This is the anemia of inflammation; too little hepcidin does the opposite and lets iron flood in (overload).

**Worked problem.** Made-up round numbers for an adult human at steady state: blood volume 5.0 L; 5.0 x 1012 red cells per L; hemoglobin 150 g per L; mean lifespan 120 days; 3.46 mg iron per g hemoglobin (4 x 55.85 = 223.4 g of iron per mol of a tetramer of about 64,500 g per mol). Assume production equals removal, every cell lives the same time, no blood loss, and all hemoglobin iron is recycled.

1. Total red cells = 5.0 x 1012 per L x 5.0 L = 2.5 x 1013 cells.
2. Production = 2.5 x 1013 / 120 days = 2.08 x 1011 cells per day; divided by 86,400 s per day, 2.4 x 106 cells per second.
3. Total hemoglobin = 150 g per L x 5.0 L = 750 g; turnover = 750 g / 120 days = 6.25 g per day.
4. Iron moved = 6.25 g per day x 3.46 mg per g = 21.6 mg per day. Reviews give 20 to 25 mg a day recycled by macrophages against 1 to 2 mg absorbed: over 90 percent of the marrow’s iron is recycled.
5. Iron in circulating hemoglobin = 750 g x 3.46 mg per g = 2,600 mg, about 2.6 g.
6. Perturbation: if hemolysis shortened lifespan to 30 days with hemoglobin held constant, production must rise fourfold, to 8.3 x 1011 cells per day, and hemoglobin iron flux to 750 / 30 x 3.46 = 86.5 mg per day. If reticulocytes stay recognizable in blood for about one day, their share rises from about 1/120 = 0.8 percent to 1/30 = 3.3 percent.

Read step 4 back as physiology: that recycling is why 1 to 2 mg absorbed a day can keep 2.4 million new cells a second in hemoglobin. The diet tops up a loop; it does not fill the tank.

## Two highland peoples, two answers to thin air

In a lowlander at altitude, hemoglobin mass rises only gradually, about 1 percent per 100 hours of exposure in pooled data from athletes, so the early hematocrit change is mostly the denominator moving. And raising hemoglobin is not the universal human answer to thin air: Beall and colleagues (1998) measured Tibetans and Bolivian Aymara at 3,800 to 4,065 m with the same technique, and Tibetan values sat close to a sea-level sample while Aymara values sat 3 to 4 g per dL higher. In 2010, variants at **EPAS1**, the gene for HIF-2 alpha, were associated with lower hemoglobin in Tibetans. These are associations in two populations; the numbers and the other caveats are in Going deeper.

Why might more hemoglobin not be better? Hemoglobin carries about 1.34 mL of oxygen per g ([oxygen transport](https://stemhop.com/lessons/oxygen-transport/)), so more red cells per litre means more oxygen per litre — but red cells also thicken blood, and viscosity rises steeply and nonlinearly with hematocrit, most of all at low shear (deformability offsets part of the cost in microvessels). Delivery is flow times content, so a high hematocrit raises content while tending to lower flow. In the excessive erythrocytosis of some Andean residents, then, predict hematocrit, viscosity, oxygen content per litre at a given saturation, and resistance to flow all to rise together.

## A cut seals while the circulation does not

So the question is not *how* fibrin forms. It is **where**, and **how much**.

> **The one idea to carry through this half of the lesson.** Thrombin is made on surfaces, not in solution. A small, self-limiting trickle is made on the tissue factor-bearing cells that the broken wall exposes. The large burst is made only on the membrane of the activated platelets that the plug has anchored at the breach. Away from that surface, flow carries thrombin off and the brakes on intact endothelium destroy it within a few micrometres. A clot grows where a surface holds the enzymes, and nowhere else.
>
> *Scope.* This is coagulation in a living vessel. It does not describe the prothrombin time and the aPTT, run in a tube with added phospholipid in place of platelets and no endothelium at all (and, for the aPTT, on an artificial contact activator) — which is exactly why those times and a patient’s bleeding can disagree. “On platelets” means chiefly platelets: any membrane that turns its phosphatidylserine outward will serve, and platelets are the surface that arrives in quantity at a wound. The distance is an order-of-magnitude estimate from diffusion and decay rates, not a measurement.

### First, the record the rule has to explain

Add a small amount of tissue factor to plasma that still contains platelets, and follow thrombin over time. Three plasmas, with made-up round numbers in the pattern these experiments give:

| Plasma | Thrombin first appears | Peak thrombin |
| --- | --- | --- |
| Normal | 4 min | 300 nM |
| Factor VIII-deficient (hemophilia A) | 4 min | 60 nM |
| Factor XII-deficient | 4 min | 290 nM |

Read the columns separately: the first is *when* thrombin starts, the second is *how much* gets made.

**Predict.** Hemophilia A causes severe bleeding into joints and muscles. Factor XII deficiency causes no abnormal bleeding at all. From the table alone, which column tracks the bleeding?

> **Check your prediction.** The size. All three plasmas start making thrombin at the same time, so starting is not what is broken in hemophilia. The factor VIII-deficient plasma reaches 60 / 300 = 20 percent of the normal peak; the factor XII-deficient plasma reaches 290 / 300, about 97 percent. The patient who bleeds is the one whose peak collapsed.
>
> So thrombin generation has two separable parts: starting, which neither deficiency touches, and amplifying, which needs factor VIII and not factor XII. That is the shape the mechanism has to have.

### The plug builds the surface

How does a procoagulant membrane get held at the breach, against flow? A cut small vessel first constricts, through reflex neurogenic mechanisms and local endothelin and platelet thromboxane A2, which slows the stream. Then **von Willebrand factor** (VWF) binds exposed collagen and the platelet receptor **GpIb**, tethering passing platelets to the wall — the step that holds against fast arterial flow. Tethered platelets activate: they release ADP, which acts on **P2Y12**, a Gi-coupled receptor ([G protein-coupled receptors](https://stemhop.com/lessons/gpcrs-and-g-proteins/)), and they make **thromboxane A2** from arachidonic acid through COX-1 and thromboxane synthase. Both recruit more platelets and switch the integrin **GpIIb/IIIa** to bind fibrinogen, which bridges neighbouring platelets into a plug. Intact endothelium alongside releases prostacyclin, which inhibits aggregation, so the plug does not spread along the wall.

## Trickle, then burst: why thrombin is made twice

The **cell-based model** (Hoffman and Monroe, 2001) places coagulation on cell surfaces in three overlapping stages — initiation, amplification and propagation.

### Stage 1: a trickle, on the cells under the wall

**Tissue factor** is a membrane protein on cells beneath the endothelium, out of contact with blood until the wall breaks. Exposed, it binds plasma **factor VIIa**, and with calcium that pair cuts factor X to **Xa** and factor IX to **IXa**.

Xa with its partner **Va** makes a little thrombin — nowhere near enough to clot anything, and it does not last, because **tissue factor pathway inhibitor** (TFPI) shuts the tissue factor-VIIa-Xa assembly down.

So why does the shut-off not end the story? The trickle was never meant to clot blood. It is a *signal*, and in the short time it exists that thrombin does four things — the amplification stage:

- activates platelets, which turn their phosphatidylserine outward and so become a procoagulant surface;
- cuts factor V to Va;
- cuts factor VIII to VIIIa, releasing it from the von Willebrand factor that carries it;
- cuts factor XI to XIa.

Thrombin builds the machine that will make thrombin in bulk.

### Stage 2: the burst, on the platelet surface

The activated platelets in the plug are the only nearby procoagulant surface anchored at the breach, and propagation happens there. Two complexes assemble on that membrane, each an enzyme plus a non-enzyme partner plus calcium, held to the exposed phosphatidylserine:

- **IXa with VIIIa** — the Xa-maker, traditionally called *intrinsic tenase*. It makes Xa, on the platelet.
- **Xa with Va** — the thrombin-maker, *prothrombinase*. It cuts prothrombin to thrombin, on the platelet.

**Predict.** The tissue factor cells were already making Xa in stage 1. Why does the platelet need its own Xa-maker, instead of using Xa that drifts over a few micrometres?

> **Check your prediction.** Because little active Xa survives in a useful form. Xa that leaves the surface where it was made is inhibited by TFPI and antithrombin in plasma and diluted by flow, and off a membrane and without Va it is a feeble prothrombin activator. So the platelet cannot rely on imported Xa. It makes its own, and that is what IXa with VIIIa is for.
>
> That is the whole of hemophilia in one sentence: **take away factor VIII or factor IX and the platelet surface has no way to supply its own Xa.** The trickle still runs, so thrombin appears on time — the first column. The burst never comes — the second.

Why is the burst so much bigger? Because holding both halves of a complex on one membrane, next to each other and next to the substrate, is worth orders of magnitude. Initiation contributes only a small fraction of a wound’s thrombin; the great majority of it, on the usual estimate well over 90 percent, is made on the platelet surface.

The burst does the visible work: thrombin cuts **fibrinogen** to fibrin, which polymerizes into a mesh through the plug, and activates **factor XIII**, which cross-links that mesh into something that holds against arterial pressure.

### Stage 3: why it stops at the edge of the wound

Thrombin made at the breach could in principle drift downstream and clot the next vessel. It does not, and the reason is a distance.

Thrombin is a small protein, so it diffuses at about 6 x 10−7 cm2 per s, and **antithrombin**, at roughly 2.5 µM in plasma, destroys it, along with factors IXa, Xa, XIa and XIIa. Those two numbers set a reach.

> **reach = square root of (D / k)**, for a molecule destroyed at a steady first-order rate everywhere it diffuses, ignoring flow — which only shortens it

- In open plasma, antithrombin alone gives thrombin a half-life of tens of seconds and a reach of **tens of micrometres** — about the width of a small vessel, already local on the scale of a body.
- On intact endothelium, heparan sulfate on the cell surface accelerates antithrombin, the chemistry heparin exploits as a drug — by a factor of order a hundred to a thousand, depending on how much of the surface carries the antithrombin-binding sugar. The half-life falls to a fraction of a second and the reach to **one to five micrometres**: one to a few cell thicknesses.

Flow takes the rest. Three further brakes sharpen the edge, all properties of the intact lining: **thrombomodulin** binds thrombin and turns it into an activator of **protein C**, which inactivates the Va and VIIIa the burst depends on; TFPI has already closed initiation; and endothelial prostacyclin and nitric oxide keep passing platelets from activating. Later, **plasmin** dissolves fibrin — endothelial tPA makes it from plasminogen docked on fibrin lysines, and fibrin potentiates tPA strongly, so lysis stays on the clot; plasminogen activator inhibitor restrains tPA, and alpha-2 antiplasmin restrains free plasmin.

Read the mechanism against the rule once more: the plug puts a surface where the wall is broken, the trickle switches it on, the burst happens on it, and the brakes make “on it” mean within a few micrometres. That is why a clot in your finger and liquid blood in your lung coexist, with the same proteins in both.

## Two tubes, then hemophilia

Most students meet clotting as a Y-shaped cascade with an “intrinsic” and an “extrinsic” arm. Those arms are not parallel routes in the body; they map two laboratory tests, each an experiment with a stated surface. The **prothrombin time** starts clotting in citrated plasma with tissue factor and calcium, so it reports factor VII and what lies downstream: X, V, prothrombin, fibrinogen. The **aPTT** starts it on an artificial contact activator, through factor XII, so it reports what that surface needs: XII, XI, IX, VIII and the same downstream set. Neither tube holds the activated platelet membrane where the burst happens.

Hemophilia A (factor VIII) and B (factor IX) are X-linked recessive, so they mainly affect males ([sex linkage and beyond](https://stemhop.com/lessons/sex-linkage-and-beyond/)). Platelets are normal, so a plug forms, and tissue factor with VIIa still makes a little Xa and thrombin, so the prothrombin time is normal. But without either factor the burst falls short; in experiments where fibrin is made at low thrombin concentrations it forms late, as a loose network of thick, sparse fibers, and the plug does not hold — which fits the joint and muscle bleeding of severe disease. The aPTT, which runs through IX and VIII, is prolonged. A two-pathway scheme cannot explain this: with parallel routes, the intact extrinsic one should suffice.

Factor XII deficiency prolongs the aPTT and causes no abnormal bleeding: factor XII drives the test’s contact activation and is not required for hemostasis. Severe factor XI deficiency usually causes milder, variable bleeding, often only after surgery or injury, which fits XI as an amplifier that thrombin can activate on platelets (how XI is activated in the body is in Going deeper). Von Willebrand factor deficiency impairs adhesion and also lowers factor VIII, which VWF carries, so it hits both halves of the story.

**Predict.** Emicizumab, first approved in the US in 2017, is a bispecific antibody that binds IXa and factor X at once, bridging them the way VIIIa does. Give it to the hemophilia A plasma from the table: what happens to the lag, and what happens to the peak?

> **Check your prediction.** The lag barely moves, because nothing was wrong with it: the trickle never needed factor VIII. The peak rises, though not to normal, because the bridge partly restores what the platelet surface was missing, a way to make its own Xa. Emicizumab is not factor VIII and does not have to be; it only has to hold IXa and X together on the membrane. That is the cell-based model put to work.

## One drug, one target

Aspirin acetylates **COX-1** covalently, at the active site, so the block is irreversible: once a platelet’s COX-1 is acetylated, that platelet cannot make thromboxane A2 again. And a platelet has no nucleus and makes little protein, so it cannot replace the enzyme. Function returns only as megakaryocytes in the marrow, which do have nuclei, release new platelets — over about a week. One dose, one platelet lifetime.

The simulation puts that on two clocks: platelets replaced over days, red cells over 120.

*Interactive on the lesson page:* One block, one lifespan: how fast function comes back

Each drug class has one main target, but the targets are not all the same kind of thing. Three act on an enzyme’s active site: aspirin on COX-1, and the direct factor Xa and thrombin inhibitors on their enzymes. One acts on a receptor: clopidogrel’s active metabolite binds P2Y12 covalently and irreversibly. One acts on an inhibitor it accelerates rather than on a clotting enzyme: heparin, through a specific pentasaccharide, accelerates antithrombin about 1000-fold. And one acts on a vitamin-recycling enzyme upstream of six proteins: warfarin inhibits vitamin K epoxide reductase, so new factors II, VII, IX and X lack the gamma-carboxylation that lets them bind calcium — and proteins C and S are vitamin K-dependent too, with protein C falling early, so the full effect waits days while existing factors are cleared.

### Design problem

In a study modelled on Renne and colleagues (2005), factor XII-null mice are compared with littermates. Illustrative results: the null mice have a prolonged aPTT, the same tail-bleeding time, and fewer occluded arteries after a chemical injury to the artery wall, and they are protected from thromboembolism induced by injected collagen plus epinephrine. What do these results rule in and out, and what would you do next?

> **One way to do it.** Tail bleeding measures **hemostasis**, stopping blood loss from a cut; occlusion and thromboembolism measure **thrombosis**, an occlusive clot inside a vessel. Normal on the first and protected on the second, in this model factor XII contributes to thrombosis but not hemostasis.
>
> The long aPTT does not contradict this: that assay requires factor XII, while a cut exposes tissue factor.
>
> Next, a rescue: restore factor XII to null mice, for example by infusing the purified protein. If occlusion returns, the missing protein caused the defect, not a linked gene or a developmental effect. Use littermates, blind scoring and two injury models.
>
> The same reasoning made factor XI a target for new anticoagulants.
>
> What it cannot show: mouse injury models are not human thrombosis, and the result says nothing about safety in people.

## Going deeper

### Spun, measured and whole-body hematocrit

Whole-body hematocrit is about 0.91 of venous hematocrit, because hematocrit is lower in the microcirculation; a spun column also traps a few percent of plasma; and modern analyzers do not spin at all, but compute hematocrit as mean cell volume times red cell count. So a venous 44 percent with 5.0 L of blood gives 2.2 L of red cells by direct multiplication, where the whole-body figure is nearer 0.91 x 2.2 = 2.0 L, about 9 percent lower.

### Which kidney cells, and how variable the lifespan is

Lacombe and colleagues (1988) localized Epo mRNA to peritubular cells and judged them most likely endothelial; later work identified them as fibroblast-like interstitial cells. In situ hybridization places a message in a region more reliably than it names a cell type.

The commonly cited peak for plasma erythropoietin (EPO) activity in hypoxic lowlanders is about 48 hours, but reported peaks range from about a day to a few days with the altitude and the protocol.

In a biotin-labelling study of six people without diabetes, the mean age of circulating red cells ranged from 38 to 60 days. Mean age is half the lifespan for cells that all live the same time, so that implies roughly 76 to 120 days.

### The highland comparison, in numbers

Beall and colleagues (1998) screened their samples to remove iron deficiency, abnormal hemoglobins and thalassemia, each of which shifts hemoglobin for reasons unrelated to altitude. Tibetan men averaged 15.6 g per dL and women 14.2, against 19.2 and 17.8 in Aymara men and women, and most of the variance within each population was attributed to genetic factors (0.86 in Tibetans, 0.87 in Aymara). In 2010, in Tibetans at 4,200 and 4,300 m, EPAS1 variants were associated with hemoglobin about 0.8 g per dL lower in major-allele homozygotes than in heterozygotes; that region was later traced to interbreeding with Denisovans ([human evolution](https://stemhop.com/lessons/human-evolution/)).

Not shown: that low hemoglobin is itself the trait selection acted on (the 2010 authors allowed another effect of the variants), how the variants change HIF-2 alpha signalling, or that either population is better adapted overall. Tibetan hemoglobin does rise above about 4,000 m. In vitro, doubling hematocrit raises viscosity about 3- to 4-fold at high shear and almost 10-fold at low shear, where red cells aggregate.

### Flow, not just chemistry, keeps thrombin local

Near the wall of a small artery at a shear rate of 103 per s, blood moves at about 1.6 mm per s even 1.6 µm out from the surface, and about 10 mm per s ten micrometres out. Comparing that transport with diffusion (the Peclet number, speed times distance divided by D) gives about 20 at one micrometre, about 40 at 1.6 micrometres and of order 103 at ten, so by ten micrometres out washout beats diffusion by orders of magnitude. Fibrin, for its part, potentiates tPA about 500-fold.

### How aspirin’s target was identified

Vane’s 1971 finding that aspirin blocks prostaglandin synthesis is in [fatty acid synthesis](https://stemhop.com/lessons/fatty-acid-synthesis/). But aspirin acetylates many proteins, so was cyclo-oxygenase itself the covalent target? Roth, Stanford and Majerus (1975) incubated sheep and bovine seminal-vesicle microsomes with aspirin whose acetyl group carried tritium and ran an SDS gel. Nonspecific acetylation would spread label over many bands; instead one protein of about 85,000 molecular weight took it up, with the same time course and concentration dependence as the loss of cyclo-oxygenase activity, and a corresponding protein was labelled in aspirin-treated human platelets. That ruled in an active-site acetylating agent. It did not show the antiplatelet effect itself, which the authors said the acetylation may account for, nor the residue (later work places it at serine 529 or 530, depending on species and numbering), nor anything about bleeding.

### How factor XI is activated in the body

Thrombin can activate factor XI on platelets, and the contact surface activates it in the aPTT tube. How much each route contributes in a person is not settled — another reason the factor XII mouse result does not transfer to human thrombosis without more evidence.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/blood-cells-and-hemostasis/
